Clearside Biomedical (NASDAQ:CLSD) Given "Buy" Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD - Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $6.00 price objective on the stock. HC Wainwright also issued estimates for Clearside Biomedical's Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.45) EPS.

Other research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Clearside Biomedical from a "hold" rating to a "sell" rating in a report on Tuesday, March 18th. Chardan Capital reissued a "buy" rating and set a $6.00 price objective on shares of Clearside Biomedical in a research note on Friday, March 28th. Finally, Needham & Company LLC decreased their target price on Clearside Biomedical from $6.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday, March 28th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $5.25.

Clearside Biomedical Trading Down 2.2 %

Shares of NASDAQ CLSD traded down $0.02 during mid-day trading on Monday, hitting $0.88. The company had a trading volume of 102,260 shares, compared to its average volume of 350,292. The stock's 50-day moving average price is $0.96 and its 200-day moving average price is $1.04. The company has a market capitalization of $67.89 million, a price-to-earnings ratio of -1.96 and a beta of 2.03. Clearside Biomedical has a 1 year low of $0.77 and a 1 year high of $1.65.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.27 million. As a group, equities research analysts forecast that Clearside Biomedical will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On Clearside Biomedical

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in shares of Clearside Biomedical by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 731,386 shares of the company's stock valued at $929,000 after purchasing an additional 59,089 shares during the last quarter. Northern Trust Corp boosted its stake in Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company's stock worth $157,000 after buying an additional 32,048 shares in the last quarter. Finally, Investor s Fiduciary Advisor Network LLC bought a new position in Clearside Biomedical during the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 18.75% of the company's stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.